18F-labeled novel tetrazines imaging probes for pretargeting in PET imaging
US12226495B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 25, 2020 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Mar 2, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel 18F-labelled tetrazines are provided which are highly reactive to be effective in vivo, suitable for pretargeted positron emission tomography (PET) and accessible in radiochemical yields (RCYs) which allow access to 18F-labeled tetrazines for clinical applications. The 18F-labelled tetrazines are developed using a Cu-mediated click indirect labelling approach. Only a subset of compounds appeared to be suitable for clinical pretargeted imaging strategies, and a particular compound which includes the use of an 18F-labelled azide synthon having an azide structure with glucose as the linker and a triazole moiety within the linker, appears to be highly suited for clinical pretargeted imaging purposes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.